Laboratory Corporation of America Holdingss in-depth stock price analysis indicates that the stock price has rallied 7.15% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -0.76% . Looking at the past 52 week period, the stock price is up at 31.05% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Laboratory Corporation of America Holdings has a positive value of 9.6 compared to overall market. Laboratory Corporation of America Holdings (NYSE:LH) has tumbled 1.95% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 0.51% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 2.74%. Laboratory Corporation of America Holdings (NYSE:LH) has underperformed the index by 1.29% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Laboratory Corporation of America Holdings (NYSE:LH) : On Friday heightened volatility was witnessed in Laboratory Corporation of America Holdings (NYSE:LH) which led to swings in the share price. The stock opened for trading at $133.84 and hit $135.76 on the upside , eventually ending the session at $135.01, with a gain of 0.88% or 1.18 points. The heightened volatility saw the trading volume jump to 1,091,030 shares. The 52-week high of the share price is $141.32 and the company has a market cap of $13,906 million. The 52-week low of the share price is at $100.98 .
Laboratory Corp. of America Holdings Last issued its quarterly earnings results on Oct 26, 2016. The company reported $2.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.04. Analyst had a consensus of $2.29. The company had revenue of $2372.70 million for the quarter, compared to analysts expectations of $2375.79 million. The companys revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.07 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Laboratory Corp. of America Holdings was Downgraded by Robert W. Baird on Feb 6, 2017 to Neutral, Price Target of the shares are set at $138.Laboratory Corp. of America Holdings was Initiated by Deutsche Bank on Jan 18, 2017 to Buy, Price Target of the shares are set at $170.
Company has reported several Insider transactions to the SEC, on Aug 11, 2016, Lisa J Uthgenannt (Chief Human Resources Officer) sold 1,177 shares at 140.00 per share price.On Aug 8, 2016, Glenn A Eisenberg (Chief Financial Officer, EVP) sold 8,000 shares at 140.38 per share price.On Aug 8, 2016, Robert E Jr Mittelstaedt (director) sold 992 shares at 140.15 per share price.
Laboratory Corporation of America Holdings, is one of the largest independent clinical laboratory companys in the United States. Through a national network of laboratories, the company offers different clinical laboratory tests which are used by the medical profession in routine testing, patient diagnosis, and in the monitoring and treatment of disease.